100 related articles for article (PubMed ID: 17966213)
1. Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation.
Paulsen T; Ree AH; Kaern J; Kjaerheim K; Bassarova A; Berner A; Haldorsen T; Tropé C; Nesland JM
Eur J Gynaecol Oncol; 2007; 28(5):356-63. PubMed ID: 17966213
[TBL] [Abstract][Full Text] [Related]
2. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
4. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas.
Munaut C; Noël A; Hougrand O; Foidart JM; Boniver J; Deprez M
Int J Cancer; 2003 Oct; 106(6):848-55. PubMed ID: 12918061
[TBL] [Abstract][Full Text] [Related]
6. Increased shear stress with upregulation of VEGF-A and its receptors and MMP-2, MMP-9, and TIMP-1 in venous stenosis of hemodialysis grafts.
Misra S; Fu AA; Puggioni A; Karimi KM; Mandrekar JN; Glockner JF; Juncos LA; Anwer B; McGuire AM; Mukhopadhyay D
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2219-30. PubMed ID: 18326810
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases.
Wang FQ; So J; Reierstad S; Fishman DA
Int J Cancer; 2006 Feb; 118(4):879-88. PubMed ID: 16152587
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
Jobim FC; Xavier NL; Uchoa DM; Cruz DB; Saciloto M; Chemello N; Schwartsmann G
Braz J Med Biol Res; 2009 Oct; 42(10):979-87. PubMed ID: 19787153
[TBL] [Abstract][Full Text] [Related]
9. Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases.
Tang C; Luo D; Yang H; Wang Q; Zhang R; Liu G; Zhou X
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):386-94. PubMed ID: 23343958
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.
Määttä M; Santala M; Soini Y; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Tumour Biol; 2004; 25(4):188-92. PubMed ID: 15557756
[TBL] [Abstract][Full Text] [Related]
14. Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor.
Lou G; Gao Y; Ning XM; Zhang QF
World J Gastroenterol; 2005 Aug; 11(32):5032-6. PubMed ID: 16124061
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity.
Ottino P; Finley J; Rojo E; Ottlecz A; Lambrou GN; Bazan HE; Bazan NG
Mol Vis; 2004 May; 10():341-50. PubMed ID: 15162095
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
17. Davallia bilabiata exhibits anti-angiogenic effect with modified MMP-2/TIMP-2 secretion and inhibited VEGF ligand/receptors expression in vascular endothelial cells.
Liu CT; Bi KW; Huang CC; Wu HT; Ho HY; S Pang JH; Huang ST
J Ethnopharmacol; 2017 Jan; 196():213-224. PubMed ID: 27993633
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
[TBL] [Abstract][Full Text] [Related]
19. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
[TBL] [Abstract][Full Text] [Related]
20. Effect of hormone replacement therapy in matrix metalloproteinase expression and intimal hyperplasia development after vascular injury.
Mountain DJ; Freeman MB; Kirkpatrick SS; Cook RB; Chalk JE; Stevens SL; Goldman MH; Grandas OH
Ann Vasc Surg; 2013 Apr; 27(3):337-45. PubMed ID: 23088810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
